Adrenoleukodystrophy: Subcellular localization and degradation of adrenoleukodystrophy protein (ALDP/ABCD1) with naturally occurring missense mutations
Abstract
Mutation in the X‐chromosomal adrenoleukodystrophy gene (ALD; ABCD1) leads to X‐linked adrenoleukodystrophy (X‐ALD), a severe neurodegenerative disorder. The encoded adrenoleukodystrophy protein (ALDP/ABCD1) is a half‐size peroxisomal ATP‐binding cassette protein of 745 amino acids in humans. In this study, we chose nine arbitrary mutant human ALDP forms (R104C, G116R, Y174C, S342P, Q544R, S606P, S606L, R617H, and H667D) with naturally occurring missense mutations and examined the intracellular behavior. When expressed in X‐ALD fibroblasts lacking ALDP, the expression level of mutant His‐ALDPs (S606L, R617H, and H667D) was lower than that of wild type and other mutant ALDPs. Furthermore, mutant ALDP‐green fluorescence proteins (S606L and H667D) stably expressed in CHO cells were not detected due to rapid degradation. Interestingly, the wild type ALDP co‐expressed in these cells also disappeared. In the case of X‐ALD fibroblasts from an ALD patient (R617H), the mutant ALDP was not detected in the cells, but appeared upon incubation with a proteasome inhibitor. When CHO cells expressing mutant ALDP‐green fluorescence protein (H667D) were cultured in the presence of a proteasome inhibitor, both the mutant and wild type ALDP reappeared. In addition, mutant His‐ALDP (Y174C), which has a mutation between transmembrane domain 2 and 3, did not exhibit peroxisomal localization by immunofluorescense study. These results suggest that mutant ALDPs, which have a mutation in the COOH‐terminal half of ALDP, including S606L, R617H, and H667D, were degraded by proteasomes after dimerization. Further, the region between transmembrane domain 2 and 3 is important for the targeting of ALDP to the peroxisome.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The pathogenic variant p.Ser606Leu affects ATP-binding capacity and results in deficient VLCFA beta-oxidation.
“Studies using experimental cell lines showed that the pathogenic variant affects ATP-binding capacity (Database Refs 194 and 244) [22,23], resulting in deficient VLCFA beta-oxidation (Database Ref 261) [24].”
From Structure and Function of the ABCD1 Variant Database: 20 Years, 940 Pathogenic Variants, and 3400 Cases of Adrenoleukodystrophy (2022) · cites this paper as [24]
Cites
Kemp, S., Pujol, A., Waterham, H. R., van Geel, B. M., Boehm, C. D., Raymond, G. V., Cutting, G. R., Wanders, R. J. A., & Moser, H. W. (2001) · Human Mutation · doi:10.1002/humu.1227 · Cited by 332 · see citing works
Adrenoleukodystrophy: Incidence, new mutation rate, and results of extended family screening
Bezman, L., Moser, A. B., Raymond, G. V., Rinaldo, P., Watkins, P. A., Smith, K. D., Kass, N. E., & Moser, H. W. (2001) · Annals of Neurology · doi:10.1002/ana.101 · Cited by 324 · see citing works
Halbach, A., Lorenzen, S., Landgraf, C., Volkmer-Engert, R., Erdmann, R., & Rottensteiner, H. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501750200 · Cited by 78 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Kawaguchi, K., & Morita, M. (2016) · BioMed Research International · doi:10.1155/2016/6786245 · Cited by 81 · see citing works
Self-citationMallack, E. J., Gao, K., Engelen, M., & Kemp, S. (2022) · Cells · doi:10.3390/cells11020283 · Cited by 60 · see citing works
“Studies using experimental cell lines showed that the pathogenic variant affects ATP-binding capacity (Database Refs 194 and 244) [22,23], resulting in deficient VLCFA beta-oxidation (Database Ref 261) [24].”
Background
- Authors
- Takahashi, N., Morita, M., Maeda, T., Harayama, Y., Shimozawa, N., Suzuki, Y., Furuya, H., Sato, R., Kashiwayama, Y., & Imanaka, T.
- Affiliations
- University of Toyama (JP)
- Gifu University (JP)
- Omuta hospital (JP)
- The University of Tokyo (JP)
- ORCID
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2007-01-22
- Volume
- 101
- Issue
- 6
- Pages
- 1632-1643
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W2003220669
- Cited by
- 28
- References
- 3
- Citations by year
- 2025: 2 · 2022: 2 · 2020: 2 · 2019: 1 · 2018: 2 · 2017: 3 · 2016: 1 · 2014: 2 · 2013: 2 · 2012: 3
- FWCI
- 0.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Neurochemistry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Kaken Pharmaceutical
- Fujita Health University
- Research Committee for Ataxic Disease
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Health Sciences › Medicine › Physiology › Lysosomal Storage Disorders Research
- Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
- Keywords
- adrenoleukodystrophy, ABCD1, ALDP, missense mutations, protein degradation, proteasome, subcellular localization, peroxisome targeting, transmembrane domain, protein dimerization, X-linked adrenoleukodystrophy
- MeSH terms
- ATP Binding Cassette Transporter, Subfamily D, Member 1, Acetylcysteine, Adrenoleukodystrophy, Animals, Cricetulus, Fibroblasts, Cricetinae, Humans, Leupeptins, Subcellular Fractions, CHO Cells, ATP-Binding Cassette Transporters, Mutation, Missense, Proteasome Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review